Form 4: Mirum Pharmaceuticals Director Laura Brege Acquires Stock Options and Restricted Stock Units

Director Laura Brege reports acquisition of stock options and restricted stock units in Mirum Pharmaceuticals.

Summary

• On June 5, 2024, Laura Brege, a director of Mirum Pharmaceuticals, acquired 8,779 stock options with an exercise price of $26.30.
• These options vest on the first anniversary of the grant date but will be fully vested by the date of the company's 2025 annual stockholder meeting.
• Brege also acquired 5,703 restricted stock units (RSUs) on the same date.
• Each RSU represents a contingent right to receive one share of Mirum Pharmaceuticals' common stock and will vest on the first anniversary of the grant date, with full vesting by the 2025 annual stockholder meeting.
• Following these transactions, Brege directly owns 8,779 stock options and 5,703 RSUs.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisition of stock options and RSUs can be seen as a positive sign of confidence, but it's not a major event.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedules of the stock options and RSUs are tied to the first anniversary of the grant date and the company's 2025 annual stockholder meeting, suggesting a focus on long-term performance and alignment with shareholder interests.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, which can be informative for investors.

Stakeholder Impact

• The acquisition of stock options and RSUs by a director can positively influence shareholder sentiment.

Key Dates